Uterine Fibroid Clinical Trials
Here are the 0 most popular medical studies for uterine fibroid
Uterine Fibroid Clinical Trials With No Placebo
View 7 uterine fibroid medical studies that do not have a placebo group.
Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
Relugolix for Uterine Fibroids
This trial aims to understand how a 4-year treatment with a relugolix combination tablet affects bone mineral density in premenopausal women with heavy bleeding or endometriosis pain.
Frequently Asked Questions
Introduction to uterine fibroid
What are the top hospitals conducting uterine fibroid research?
When it comes to advancing the treatment options for uterine fibroids, there are hospitals across different locations that are actively involved in clinical trials. In Chandler, Arizona, the Chandler Hospital is currently conducting two ongoing trials focused on uterine fibroids. This condition, characterized by non-cancerous growths in the uterus, affects many women worldwide but has seen limited research attention until recently. Similarly, Canoga Park Hospital in California and Hialeah Hospital in Florida also have two active clinical trials dedicated to uterine fibroids. These hospitals recognize the importance of expanding knowledge and exploring innovative treatments for this common gynecological issue.
Heading further eastward to Lake Worth and Miami in Florida, we find two more institutions at the forefront of uterine fibroid research. Both Lake Worth Hospital and Miami Hospital are currently running two active clinical trials centered around this condition. Uterine fibroids can cause significant symptoms such as heavy menstrual bleeding or pelvic pain; hence understanding their development and finding effective therapies is crucial for improving quality of life for affected individuals.
While these hospitals may not have a recorded history of completed trials specific to uterine fibroids just yet (as indicated by zero all-time trials), their commitment to investigating potential solutions shows promise for future breakthroughs in addressing this common health concern among women. By participating in these studies or seeking out new treatment options available through such clinical trials at these esteemed medical centers, patients with uterine fibroids can contribute towards advancements that may lead to better outcomes and improved care strategies going forward
Which are the best cities for uterine fibroid clinical trials?
When it comes to uterine fibroid clinical trials, several cities have emerged as leaders in research and development. Among them, Atlanta, Georgia stands out with 9 active trials investigating treatments like Elagolix, Vilaprisan (BAY1002670), and Relugolix Combination Tablet. Tucson, Arizona follows closely behind with 7 ongoing studies focused on therapies such as Relugolix Combination Therapy and Elagolix. Miami, Florida and San Diego, California both have 6 active trials exploring various treatment options including Elagolix and Relugolix Combination Therapy. Additionally, Mobile, Alabama is conducting 5 active trials examining potential breakthroughs like Vilaprisan (BAY1002670) and the Relugolix Combination Tablet. These cities offer individuals dealing with uterine fibroids access to cutting-edge clinical trials that pave the way for improved care and better outcomes.
Which are the top treatments for uterine fibroid being explored in clinical trials?
Uterine fibroids are a common concern for many women, and ongoing clinical trials are actively exploring potential treatments to address this condition. Among the promising options being investigated in these trials are:
- Elagolix: Currently involved in six active uterine fibroid trials, with significant research interest over time.
- Vilaprisan: Being tested in three active clinical trials for uterine fibroids, showing promise as a potential treatment option.
- Relugolix: Engaged in two ongoing trials specifically focused on treating uterine fibroids.
These innovative treatments hold the potential to revolutionize how we manage and alleviate the symptoms of uterine fibroids, providing hope for countless women worldwide.
What are the most recent clinical trials for uterine fibroid?
Exciting developments are underway in the realm of uterine fibroid treatment, with recent clinical trials shedding light on potential breakthroughs. Amongst these trials, a Phase 3 study investigated the efficacy of the Relugolix Combination Tablet as a treatment for uterine fibroids. Another Phase 3 trial examined the effectiveness of Relugolix Combination Therapy in addressing this condition. Furthermore, Elagolix was evaluated in a Phase 3 trial to assess its impact on uterine fibroids. Additionally, Vilaprisan (BAY1002670) underwent a Phase 3 study exploring its potential benefits for individuals with this condition. These studies mark significant milestones towards improved options and outcomes for those living with uterine fibroids.
What uterine fibroid clinical trials were recently completed?
Recent advancements in the field of uterine fibroid research have led to the completion of several significant clinical trials. In April 2019, Inovio Pharmaceuticals concluded a trial investigating VGX-3100 as a potential treatment option. University of Arkansas also completed their PepCan trial in November 2015. Additionally, in November 2008, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins wrapped up their pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine study. These trials represent important progress in understanding and addressing uterine fibroids, bringing hope for improved treatments and outcomes for affected individuals.